ImaginAb and Imanet enter master service agreement for pre-clinical and clinical imaging

ImaginAb, Inc. and Imanet (part of GE Healthcare) have signed a master service agreement for pre-clinical and clinical imaging. This agreement supports the development strategy for ImaginAb's pipeline of next generation diagnostic imaging agents based on recombinant antibody fragments. The Imanet™ network of Positron Emission Tomography (PET) imaging sites provides assistance in all aspects of PET imaging-based clinical trials: from proof-of-concept radiochemistry to clinical imaging, with more than 40 PET research tracers.  

"ImaginAb is pleased to have formalized this agreement with Imanet", said Dr. Christian Behrenbruch, CEO of ImaginAb. "Imanet's superb network of pre-clinical and clinical imaging sites and leveraging GE's expertise in radiochemistry will be invaluable for both our internal product pipeline as well as for ImaginAb's pharmaceutical partnerships.  We also intend to work with Imanet to validate our library of pre-clinical imaging probes for microPET and microSPECT imaging".

Molecular imaging using recombinant antibody fragments has emerged over the last decade as a flexible research platform for targeting diagnostic and prognostic biomarkers potentially beneficial for the development of molecular therapies by the biopharmaceutical industry.  ImaginAb's recombinant antibody fragments enable development of tailored, highly specific imaging agents for drug research.  ImaginAb's imaging agent development will benefit from Imanet's PET infrastructure, know-how and nearly 10 years in conducting PET studies with high sensitivity and image resolution for drug development.

Dr. Eric Agdeppa, Imaging Solutions Manager of Imanet, commented, "ImaginAb's technology shows tremendous potential to address a wide range of unmet needs in clinical imaging.  ImaginAb has an extensive pipeline of new products that we are pleased to help develop. We also see synergy between Imanet's capabilities and ImaginAb's rapidly growing pharmaceutical industry clientele."